COMP <GO>
MDLN vs ABBV // FREE CASH FLOW YIELD
Medline Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: MDLN 5
— ABBV 10
▲ FREE CASH FLOW YIELD LEADER: ABBV
LAST: $32.12 (+0.38%) • MKT CAP: $42.07B
fcf-yield
3.08%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDLN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDLN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 26.40% | 70.20% | -43.80 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.20% | 29.00% | -20.80 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.3x | 33.3x | -13.00 | MDLN | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 3.08% | 3.47% | -0.39 | ABBV | /fcf-yield <GO> |
| Operating Margin | 7.80% | 24.60% | -16.80 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 6.90% | +61.10 | MDLN | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 8.60% | +2.90 | MDLN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.50 | 5.33 | -2.83 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 7.40% | -0.10 | MDLN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 31.6 | 72.8 | -41.22 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 1.15 | -0.04 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 4.2x | 113.1x | -108.90 | MDLN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.07B | $513.86B | -$471.79B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDLN REV | ABBV REV | MDLN GROSS % | ABBV GROSS % | MDLN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $28.43B | $61.16B | 26.4% | 70.2% | $1.30B | $17.82B |
| FY 2024 | $25.51B | $56.33B | 27.3% | 70.0% | $1.42B | $17.83B |
| FY 2023 | $23.23B | $54.32B | 44.0% | 44.0% | $639.6M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDLN // BETA 1.11
ABBV // BETA 1.15